Associations between m6A related-mRNA <i>IFIT5</i> and systemic lupus erythematosus

WU Jun; LI Shangjie; ZHANG Jie; YE Dongqing; NI Jindong

doi:10.16462/j.cnki.zhjbkz.2023.12.015

Volume 27 Issue 12

Dec. 2023

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2023 > 27(12): 1455-1460

WU Jun, LI Shangjie, ZHANG Jie, YE Dongqing, NI Jindong. Associations between m6A related-mRNA IFIT5 and systemic lupus erythematosus[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(12): 1455-1460. doi: 10.16462/j.cnki.zhjbkz.2023.12.015

Citation:

WU Jun, LI Shangjie, ZHANG Jie, YE Dongqing, NI Jindong. Associations between m6A related-mRNA IFIT5 and systemic lupus erythematosus[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2023, 27(12): 1455-1460. doi: 10.16462/j.cnki.zhjbkz.2023.12.015

Citation:

PDF( 3965 KB)

Associations between m6A related-mRNA IFIT5 and systemic lupus erythematosus

doi: 10.16462/j.cnki.zhjbkz.2023.12.015

WU Jun¹,
LI Shangjie¹,
ZHANG Jie²,
YE Dongqing^{2
,
,},
NI Jindong^{1
,
,}

1.
Department of Epidemiology and Biostatistics, School of Public Health, Guangdong Medical University, Dongguan 523808, China
2.
School of Public Health, Anhui University of Science and Technology, Hefei 231131, China

Funds:

Guangdong Basic and Applied Basic Research Foundation 2022A1515111042

The National Natural Science Foundation of China 81872693

The National Natural Science Foundation of China 81872687

More Information

Corresponding author: YE Dongqing, E-mail: anhuiydq@126.com; NI Jindong, E-mail: nijd-gw@gdmu.edu.cn
Received Date: 2023-07-31
Rev Recd Date: 2023-10-18
Publish Date: 2023-12-10

Abstract

Abstract

Objective N6-methyladenosine (m6A) methylation involved in immuno-inflammatory responses via the regulation of mRNA expression and function is reported, but its limit is in systemic lupus erythematosus (SLE). Therefore, this study will initially explore the associations of m6A-related mRNA expression with SLE. Methods Real-time quantitative polymerase chain reaction and western blot were used to validate the expression levels of m6A-related IFIT5in T cells of patients with SLE. Following that, the correlations between IFIT5and clinical characteristics, laboratory parameters and treatment of patients with SLE were analyzed. Further functional experiments were conducted to establish the Jurkat cell lines with silencing IFIT5 for exploration of the alteration of T cells and immune inflammatory cytokines (TNF-α, IL-2, and IL-6). Results Compared with normal controls, m6A modification of highly expressed IFIT5 in SLE patients was significantly enhanced. The expression levels of IFIT5 were steadily up-regulated in the T cells of patients with SLE, and were closely associated with the degree of disease activity in patients with SLE. Cell experiments showed that silencing IFIT5 significantly inhibited T cell proliferation and accelerated apoptosis, as well as triggered tumor necrosis factor-alpha (TNF-α) secretion and induced the expression levels of interleukin-2 (IL-2) and interleukin-6 (IL-6). Conclusion The high expression level of IFIT5is related to m6A modification, it is also up-regulated in the T cells of patients with SLE, which participate in the immune inflammatory responses of Jurkat cells, and the specific mechanism deserves further study.
- Systemic lupus erythematosus,
- N6-methyladenosine,
- Iinterferon induced protein with tetratricopeptide repeats 5

FullText(HTML)

References(19)

References

[1]	Basta F, Fasola F, Triantafyllias K, et al. Systemic lupus erythematosus (SLE) therapy: the old and the new[J]. Rheumatol Ther, 2020, 7(3): 433-446. DOI: 10.1007/s40744-020-00212-9.
[2]	Bentham J, Morris DL, Graham DSC, et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus[J]. Nat Genet, 2015, 47(12): 1457-1464. DOI: 10.1038/ng.3434.
[3]	Wu H, Chang C, Lu Q. The epigenetics of lupus erythematosus[J]. Adv Exp Med Biol, 2020, 1253: 185-207. DOI: 10.1007/978-981-15-3449-2_7.
[4]	Liu C, Yang Z, Li R, et al. Potential roles of N6-methyladenosine (m6A) in immune cells[J]. J Transl Med, 2021, 19(1): 251. DOI: 10.1186/s12967-021-02918-y.
[5]	Wang HM, Hu X, Huang MY, et al. Mettl3-mediated mRNA m6A methylation promotes dendritic cell activation[J]. Nat Commun, 2019, 10: 1898. DOI: 10.1038/s41467-019-09903-6.
[6]	Chen Q, Li H, Liu YS, et al. Epigenetic regulation of immune and inflammatory responses in rheumatoid arthritis[J]. Front Immunol, 2022, 13: 881191. DOI: 10.3389/fimmu.2022.881191.
[7]	Luo Q, Rao JY, Zhang L, et al. The study of METTL14, ALKBH5, and YTHDF2 in peripheral blood mononuclear cells from systemic lupus erythematosus[J]. Mol Genet Genomic Med, 2020, 8(9): e1298. DOI: 10.1002/mgg3.1298.
[8]	Luo Q, Fu BQ, Zhang L, et al. Decreased peripheral blood ALKBH5 correlates with markers of autoimmune response in systemic lupus erythematosus[J]. Dis Markers, 2020, 2020: 8193895. DOI: 10.1155/2020/8193895.
[9]	Wu J, Deng LJ, Xia YR, et al. Involvement of N6-methyladenosine modifications of long noncoding RNAs in systemic lupus erythematosus[J]. Mol Immunol, 2022, 143: 77-84. DOI: 10.1016/j.molimm.2022.01.006.
[10]	Wu YY, Xing J, Li XF, et al. Roles of interferon induced protein with tetratricopeptide repeats (IFIT) family in autoimmune disease[J]. Autoimmun Rev, 2023, 22(11): 103453. DOI: 10.1016/j.autrev.2023.103453.
[11]	Hochberg MC. Updating the american college of rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis and rheumatism, 1997, 40(9): 1725.
[12]	Li LJ, Fan YG, Leng RX, et al. Potential link between m6A modification and systemic lupus erythematosus[J]. Mol Immunol, 2018, 93: 55-63. DOI: 10.1016/j.molimm.2017.11.009.
[13]	Zhang BH, Liu XY, Chen W, et al. IFIT5 potentiates anti-viral response through enhancing innate immune signaling pathways[J]. Acta Biochim Biophys Sin (Shanghai), 2013, 45(10): 867-874. DOI: 10.1093/abbs/gmt088.
[14]	Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000[J]. The Journal of rheumatology, 2002, 29(2): 288-291.
[15]	Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology[J]. Nat Rev Rheumatol, 2020, 16(3): 155-166. DOI: 10.1038/s41584-020-0372-x.
[16]	Su R, Dong L, Li YC, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion[J]. Cancer Cell, 2020, 38(1): 79-96. e11. DOI: 10.1016/j.ccell.2020.04.017.
[17]	Li HB, Tong JY, Zhu S, et al. m6A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways[J]. Nature, 2017, 548(7667): 338-342. DOI: 10.1038/nature23450.
[18]	Yao YP, Yang Y, Guo WH, et al. METTL3-dependent m6A modification programs T follicular helper cell differentiation[J]. Nat Commun, 2021, 12(1): 1333. DOI: 10.1038/s41467-021-21594-6.
[19]	Hao H, Nakayamada S, Yamagata K, et al. Conversion of T follicular helper cells to T follicular regulatory cells by interleukin-2 through transcriptional regulation in systemic lupus erythematosus[J]. Arthritis Rheumatol, 2021, 73(1): 132-142. DOI: 10.1002/art.41457.